[11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS

Brain

Volumn 128, Issue 4, 2005, Pages 896-905

  Turner, M R ^a,b   Rabiner, E A ^b,c   Hammers, A ^b   Al Chalabi, A ^a   Grasby, P M ^b   Shaw, C E ^d   Brooks, D J ^b,e   Leigh, P N ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Amyotrophic lateral sclerosis; Motor neurone disease; PET; Serotonin 1A receptor; WAY100635

Indexed keywords

CARBON 11; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR; CARBON; DIAGNOSTIC AGENT; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN ANTAGONIST;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BRAIN MAPPING; CLINICAL ARTICLE; COGNITION; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR DEPRESSION; MALE; MOTOR NEURON DISEASE; NEUROTRANSMISSION; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; BRAIN CORTEX; DEPRESSION; EVALUATION; METABOLISM; MIDDLE AGED; PSYCHOLOGICAL ASPECT; QUALITY CONTROL; SCINTISCANNING;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; CARBON RADIOISOTOPES; CEREBRAL CORTEX; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; QUALITY CONTROL; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN ANTAGONISTS;

EID: 16844362310     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awh428     Document Type: Article

References (107)

1. Abrahams S, Goldstein LH, Kew JJ et al. Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study. Brain 1996; 119(Pt 6): 2105-20.
2. Abrahams S, Goldstein LH, Al Chalabi A et al. Relation between cognitive dysfunction and pseudobulbar palsy in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiat 1997; 62: 464-72.
3. Abrahams S, Leigh PN, Harvey A, Vythelingum GN, Grise D, Goldstein LH. Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS). Neuropsychologia 2000; 38: 734-47.
4. Abrahams S, Goldstein LH, Simmons A et al. Word retrieval in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study. Brain 2004; 127: 1507-17.
5. Anderson VE, Cairns NJ, Leigh PN. Involvement of the amygdala, dentate and hippocampus in motor neuron disease. J Neurol Sci 1995; 129 (Suppl): 75-8.
6. Antri M, Mouffle C, Orsal D, Barthe JY. 5-HT1A receptors are involved in short- and long-term processes responsible for 5-HT-induced locomotor function recovery in chronic spinal rat. Eur J Neurosci 2003; 18: 1963-72.
7. Azmitia EC. Modern views on an ancient chemical: serotonin effects on cell proliferation, maturation, and apoptosis. Brain Res Bull 2001; 56: 413-24.
8. Azmitia EC, Cannon PJ, Kheck NM, Whitaker-Azmitia PM. Cellular localization of the 5-HT1A receptor in primate brain neurons and glial cells. Neuropsychopharmacology 1996; 14: 35-46.
9. Aznar S, Qian Z, Shah R, Rahbek B, Knudsen GM. The 5-HT1A serotonin receptor is located on calbindin- and parvalbumin-containing neurons in the rat brain. Brain Res 2003; 959: 58-67.
10. Banasr M, Hery M, Printemps R, Daszuta A. Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology 2004; 29: 450-60.
11. Bertel O, Malessa S, Sluga E, Hornykiewicz O. Amyotrophic lateral sclerosis: changes of noradrenergic and serotonergic transmitter systems in the spinal cord. Brain Res 1991; 566: 54-60.
12. Bouryi VA, Lewis DI. The modulation by 5-HT of glutamatergic inputs from the raphe pallidus to rat hypoglossal motoneurones in-vitro. J Physiol 2003; 553: 1019-31.
13. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293-9.
14. Buhot MC. Serotonin receptors in cognitive behaviors. Curr Opin Neurobiol 1997; 7: 243-54.
15. Burnet PW, Eastwood SL, Lacey K, Harrison PJ. The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain. Brain Res 1995; 676: 157-68.
16. Cedarbaum JM, Stambler N, Malta E et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999; 169: 13-21.
17. Celada P, Puig MV, Casanovas JM, Guillazo G, Artigas F. Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: Involvement of serotonin-1A, GABA(A), and glutamate receptors. J Neurosci 2001; 21: 9917-29.
18. Chalmers DT, Watson SJ. Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain-a combined in situ hybridisation/in vitro receptor autoradiographic study. Brain Res 1991; 561: 51-60.
19. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001; 2: 806-19.
20. Cowen PJ. Psychopharmacology of 5-HT(1A) receptors. Nucl Med Biol 2000; 27: 437-9.
21. Cunningham V, Lammertsma A. Radioligand studies in brain: kinetic analysis of PET data. Med Chem Res 1994; 5: 79-96.
22. Czyrak A, Czepiel K, Mackowiak M, Chocyk A, Wedzony K. Serotonin 5-HT1A receptors might control the output of cortical glutamatergic neurons in rat cingulate cortex. Brain Res 2003; 989: 42-51.
23. Dalakas MC, Hatazawa J, Brooks RA, Di Chiro G. Lowered cerebral glucose utilization in amyotrophic lateral sclerosis. Ann Neurol 1987; 22: 580-6.
24. David AS, Gillham RA. Neuropsychological study of motor neuron disease. Psyehosomatics 1986; 27: 441-5.
25. De Haes JI, Bosker FJ, Van Waarde A et al. 5-HT(1A) receptor imaging in the human brain: effect of tryptophan depletion and infusion on [(18)F]MPPF binding. Synapse 2002; 46: 108-15.
26. De Vos H, Convents A, De Keyser J et al. Autoradiographic distribution of alpha 2 adrenoceptors, NAIBS, and 5-HT1A receptors in human brain using [3H]idazoxan and [3H]rauwolscine. Brain Res 1991; 566: 13-20.
27. DeFelipe J, Arellano JI, Gomez A, Azmitia EC, Munoz A. Pyramidal cell axons show a local specialization for GABA and 5-HT inputs in monkey and human cerebral cortex. J Comp Neurol 2001; 433: 148-55.
28. Doble A. The role of excitotoxicity in neurodegenerativc disease: implications for therapy. Pharmacol Ther 1999; 81: 163-221.
29. Doder M, Rabiner EA, Turjankski N, Lees AJ, Brooks DJ. Brain serotonin IA receptors in Parkinson's disease with and without depression measured by positron emission tomography and 11C-WAY 100635. Movem Disord 2000; 15: 213.
30. Eisen A, Weber M. Neurophysiological evaluation of cortical function in the early diagnosis of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1 (Suppl 1): S47-51.
31. Ellis CM, Suckling J, Amaro E Jr et al. Volumetric analysis reveals corticospinal tract degeneration and extramotor involvement in ALS. Neurology 2001; 57: 1571-8.
32. Farde L, Ito H, Swahn CG, Pike VW, Halldin C. Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man. J Nucl Med 1998; 39: 1965-71.
33. Forrest V, Ince P, Leitch M, Marshall EF, Shaw PJ. Serotonergic neurotransmission in the spinal cord and motor cortex of patients with motor neuron disease and controls: quantitative autoradiography for 5-HT1a and 5-HT2 receptors. J Neurol Sci 1996; 139(Suppl): 83-90.
34. Forster EA, Cliffe IA, Bill DJ et al. A pharmacological profile of the selective silent 5-HTIA receptor antagonist, WAY-100635. Eur J Pharmacol 1995; 281: 81-8.
35. Francis PT, Pangalos MN, Pearson RC, Middlemiss DN, Stratmann GC, Bowen DM. 5-Hydroxytryptamine1A but not 5-hydroxytryptamine2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin. J Pharmacol Exp Ther 1992; 261: 1273-81.
36. Fristen KJ, Frith CD, Liddle PF, Frackowiak RS. Comparing functional (PET) images: the assessment of significant change. J Cereb Blood Flow Metab 1991; 11: 690-9.
37. Fuxe K. Evidence for the existence of monamine neurons in hte central nervous system. IV. The distribution of monoamine terminals in the central nervous system. Acta Physiol Scand 1965; 64: 37-85.
38. Gallassi R, Montagna P, Ciardulli C, Lorusso S, Mussuto V, Stracciari A. Cognitive impairment in motor neuron disease. Acta Neurol Scand 1985; 71: 480-4.
39. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997; 6: 279-87.
40. Gunn RN, Sargent PA, Bench CJ et al. Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET. Neuroimage 1998a; 8: 426-40.
41. Gunn RN, Lammertsma AA, Cunningham VJ. Parametric imaging of ligand-receptor interactions using a reference tissue model and cluster analysis. In: Carson RE, Daube-Witherspoon ME, Herscovitch P, editors. Quantitative functional brain imaging with positron emission tomography. San Diego: Academic Press, 1998b: 401-6.
42. Hall H, Lundkvist C, Halldin C et al. Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635. Brain Res 1997; 745: 96-108.
43. Hammers A, Allom R, Koepp MJ et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp 2003; 19: 224-47.
44. Hammers A, Koepp MJ, Free SL et al. Implementation and application of a brain template for multiple volumes of interest. Hum Brain Mapp 2002; 15: 165-74.
45. Hanajima R, Ugawa Y. Impaired motor cortex inhibition in patients with ALS: evidence from paired transcranial magnetic stimulation. Neurology 1998; 51: 1771-2.
46. Hatazawa J, Brooks RA, Dalakas MC, Mansi L, Di Chiro G. Cortical motor-sensory hypometabolism in amyotrophic lateral sclerosis: a PET study. J Comput Assist Tomogr 1988; 12: 630-6.
47. Hume S, Hirani E, Opacka-Juffry J et al. Effect of 5-HT on binding of [(11)C] WAY 100635 to 5-HT(IA) receptors in rat brain, assessed using in vivo microdialysis nd PET after fenfluramine. Synapse 2001; 41: 150-9.
48. Hutton M, Lendon CL, Rizzu P et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393: 702-5.
49. Iwasaki Y, Shiojima T, Kinoshita M, Ikeda K. SR57746A: a survival factor for motor neurons in vivo. J Neurol Sci 1998; 160(Suppl 1): S92-96.
50. Kawashima T, Doh-ura K, Kikuchi H, Iwaki T. Cognitive dysfunction in patients with amyotrophic lateral sclerosis is associated with spherical or crescent-shaped ubiquitinated intraneuronal inclusions in the parahippocampal gyrus and amygdala, but not in the neostriatum. Acta Neuropathol (Berl) 2001; 102: 467-72.
51. Kew J, Leigh N. Dementia with motor neurone disease. Baillieres Clin Neurol 1992; 1: 611-26.
52. Kew JJ, Leigh PN, Playford ED et al. Cortical function in amyotrophic lateral sclerosis. A positron emission tomography study. Brain 1993; 116(Pt 3): 655-80.
53. Labie C, Lafon C, Marmouget C et al. Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex. Br J Pharmacol 1999; 127: 139-44.
54. Lacomblez L, Bensimon G, Douillet P, Doppler V, Salachas F, Meininger V. Xaliproden in amyotrophic lateral sclerosis: early clinical trials. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 99-106.
55. Ladewig T, Lalley PM, Keller BU. Serotonergic modulation of intracellular calcium dynamics in neonatal hypoglossal motoneurons from mouse. Brain Res 2004; 1001: 1-12.
56. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4: 153-8.
57. Lechtzin N, Cudkowicz ME, Clawson LL, Fogel R, Bradbury L, Hilgenberg S, Butler M, and Rothstein JD. Clinical Trial Of Buspirone In Patients With Amyotrophic Lateral Sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2(Suppl 2): 162(Abstract).
58. Leigh PN, Meldrum BS. Excitotoxicity in ALS. Neurology 1996; 47: S221-227.
59. Lloyd CM, Richardson MP, Brooks DJ, Al Chalabi A, Leigh PN. Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C] flumazenil. Brain 2000; 123(Pt 11): 2289-96.
60. Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002; 59: 1077-9.
61. Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003; 60: 1094-7.
62. Ludolph AC, Langen KJ, Regard M et al. Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta Neurol Scand 1992; 85: 81-9.
63. Maeda J, Suhara T, Ogawa M et al. In vivo binding properties of [carbonyl-11C]WAY-100635: effect of endogenous serotonin. Synapse 2001; 40: 122-9.
64. Maekawa S, Al Sarraj S, Kibble M et al. Cortical selective vulnerability in Motor Neurone Disease: A morphometric study. Brain 2004; 127: 1237-51.
65. Manaker S, Caine SB, Winokur A. Alterations in receptors for thyrotropin-releasing hormone, serotonin, and acetylcholine in amyotrophic lateral sclerosis. Neurology 1988; 38: 1464-74.
66. Massman PJ, Sims J, Cooke N, Haverkamp LJ, Appel V, Appel SH. Prevalence and correlates of neuropsychological deficits in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiat 1996; 61: 450-5.
67. McCormick DA, Williamson A. Convergence and divergence of neurotransmitter action in human cerebral cortex. Proc Natl Acad Sci USA 1989; 86: 8098-102.
68. Meininger V, Bensimon G, Bradley WR et al. Efficacy and safety of xali-proden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 107-17.
69. Moore MJ, Moore PB, Shaw PJ. Mood disturbances in motor neurone disease. J Neurol Sci 1998; 160(Suppl 1): S53-56.
70. Munte TF, Troger MC, Nusser I et al. Alteration of early components of the visual evoked potential in amyotrophic lateral sclerosis. J Neurol 1998; 245: 206-10.
71. Munte TF, Troger MC, Nusser I et al. Abnormalities of visual search behaviour in ALS patients detected with event-related brain potentials. Amyotroph Lateral Scler Other Motor Neuron Disord 1999; 1: 21-7.
72. Neary D, Snowden J. Pronto-temporal dementia: nosology, neuropsychology, and neuropathology. Brain Cogn 1996; 31: 176-87.
73. Ohsugi K, Adachi K, Mukoyama M, Ando K. Lack of change in indoleamine metabolism in spinal cord of patients with amyotrophic lateral sclerosis. Neurosci Lett 1987; 79: 351-4.
74. Pasqualetti M, Nardi I, Ladinsky H, Marazziti D, Cassano GB. Comparative anatomical distribution of serotonin 1A, 1D alpha and 2A receptor mRNAs in human brain postmortem. Brain Res Mol Brain Res 1996; 39: 223-33.
75. Paulus KS, Magnano I, Piras MR et al. Visual and auditory event-related potentials in sporadic amyotrophic lateral sclerosis. Clin Neurophysiol 2002; 113: 853-61.
76. Pekkonen E, Osipova D, Laaksovirta H. Magnetoencephalographic evidence of abnormal auditory processing in amyotrophic lateral sclerosis with bulbar signs. Clin Neurophysiol 2004; 115: 309-15.
77. Piao YS, Wakabayashi K, Kakita A et al. Neuropathology with clinical correlations of sporadic amyotrophic lateral sclerosis: 102 autopsy cases examined between 1962 and 2000. Brain Pathol 2003; 13: 10-22.
78. Pike VW, McCarron JA, Lammertsma AA et al. Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbony-11C]WAY-100635. Eur J Pharmacol 1996; 301: R5-R7.
79. Pioro EP, Antel JP, Cashman NR, Arnold DL. Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology 1994; 44: 1933-8.
80. Plaitakis A, Caroscio JT. Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol 1987; 22: 575-9.
81. Pompeiano M, Palacios JM, Mengod G. Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J Neurosci 1992; 12: 440-53.
82. Rabiner EA, Messa C, Sargent PA et al. A database of [(11)C]WAY-100635 binding to 5-HT(1A) receptors in normal male volunteers: normative data and relationship to methodological, demographic, physiological, and behavioral variables. Neuroimage 2002; 15: 620-32.
83. Rekling JC, Funk GD, Bayliss DA, Dong XW, Feldman JL. Synaptic control of motoneuronal excitability. Physiol Rev 2000; 80: 767-852.
84. Riad M, Emerit MB, Hamon M. Neurotrophic effects of ipsapirone and other 5-HT1A receptor agonists on septal cholinergic neurons in culture. Brain Res Dev Brain Res 1994; 82: 245-58.
85. Rothstein JD, Tsai G, Kuncl RW et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990; 28: 18-25.
86. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688-1700.
87. Sargent PA, Kjaer KH, Bench CJ et al. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiat 2000; 57: 174-80.
88. Schiffer D, Fiano V. Astrogliosis in ALS: possible interpretations according to pathogenetic hypotheses. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 22-5.
89. Schiffer RB, Babigian HM. Behavioral disorders in multiple sclerosis, temporal lobe epilepsy, and amyotrophic lateral sclerosis. An epidemiologic study. Arch Neurol 1984; 41: 1067-9.
90. Sharp T, Hjorth S. Application of brain microdialysis to study the pharmacology of the 5-HT1A autoreceptor. J Neurosci Meth 1990; 34: 83-90.
91. Shaw CE, Al Chalabi A, Leigh N. Progress in the pathogenesis of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep 2001; 1: 69-76.
92. Shupliakov O, Pieribone VA, Gad H, Brodin L. Synaptic vesicle depletion in reticulospinal axons is reduced by 5-hydroxytryptamine: direct evidence for presynaptic modulation of glutamatergic transmission. Eur J Neurosci 1995; 7: 1111-16.
93. Singer JH, Bellingham MC, Berger AJ. Presynaptic inhibition of glutamatergic synaptic transmission to rat motoneurons by serotonin. J Neurophysiol 1996; 76: 799-807.
94. Smith MC. Nerve fibre degeneration in the brain in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiat 1960; 23: 269-82.
95. Spinks TJ, Jones T, Bloomfield PM et al. Physical characteristics of the ECAT EXACT3D positron tomograph. Phys Med Biol 2000; 45: 2601-18.
96. Tsuchiya K, Takahashi M, Shiotsu H et al. Sporadic amyotrophic lateral sclerosis with circumscribed temporal atrophy: a report of an autopsy case without dementia and with ubiquitinated intraneuronal inclusions. Neuropathology 2002; 22: 308-16.
97. Turner MR, Leigh PN. Positron emission tomography (PET)-its potential to provide surrogate markers in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1(Suppl 2): S17-22.
98. Turner BJ, Lopes EC, Cheema SS. The serotonin precursor 5-hydroxytryptophan delays neuromuscular disease in murine familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4: 171-6.
99. Turner MR, Cagnin A, Turkheimer FE et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [(11)C](R)-PK11195 positron emission tomography study. Neurobiol Dis 2004; 15: 601-9.
100. Varnas K, Halldin C, Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp 2004; 22: 246-60.
101. Wakabayashi K, Piao YS, Hayashi S, Kakita A, Yamada M, Takahashi H. Ubiquitinated neuronal inclusions in the neostriatum in patients with amyotrophic lateral sclerosis with and without dementia-a study of 60 patients 31 to 87 years of age. Clin Neuropathol 2001; 20: 47-52.
102. Weber M, Eisen A, Stewart HG, Andersen PM. Preserved slow conducting corticomotoneuronal projections in amyotrophic lateral sclerosis with autosomal recessive D90A CuZn-superoxide dismutase mutation. Brain 2000; 123: 1505-15.
103. Whitehouse PJ, Wamsley JK, Zarbin MA, Price DL, Tourtellotte WW, Kuhar MJ. Amyotrophic lateral sclerosis: alterations in neurotransmitter receptors. Ann Neurol 1983; 14: 8-16.
104. Yan W, Wilson CC, Haring JH. 5-HT1a receptors mediate the neurotrophic effect of serotonin on developing dentate granule cells. Brain Res Dev Brain Res 1997; 98: 185-90.
105. Yang Y, Schmitt HP. Frontotemporal dementia: evidence for impairment of ascending serotoninergic but not noradrenergic innervation. Immunocytochemical and quantitative study using a graph method. Acta Neuropathol (Berl) 2001; 101: 256-70.
106. Ziemann U, Winter M, Reimers CD, Reimers K, Tergau F, Paulus W. Impaired motor cortex inhibition in patients with amyotrophic lateral sclerosis. Evidence from paired transcranial magnetic stimulation. Neurology 1997; 49: 1292-8.
107. Zimmer L, Riad M, Rbah L et al. Toward brain imaging of serotonin 5-HT(1A) autoreceptor internalization. Neuroimage 2004; 22: 1421-6.